What is the recommended first‑line treatment and dosing for seizures in a neonate?

First-Line Treatment for Neonatal Seizures

Phenobarbital 20 mg/kg IV is the recommended first-line treatment for neonatal seizures, with an additional 20 mg/kg dose if seizures persist, achieving seizure control in approximately 80% of neonates. 1

Diagnostic Confirmation

• EEG or amplitude-integrated EEG (aEEG) monitoring should be used to confirm seizures before initiating treatment, as clinical diagnosis alone is unreliable except for focal clonic or focal tonic seizures. 1
• Conventional EEG is the gold standard; aEEG is an acceptable alternative when continuous EEG is unavailable. 1
• Only focal clonic and focal tonic seizures can be diagnosed by clinical observation alone—all other seizure types require EEG/aEEG confirmation. 1

First-Line Treatment: Phenobarbital

Dosing

• Initial loading dose: 20 mg/kg IV 1
• Additional dose if seizures persist: 20 mg/kg IV (can be given after assessing response every 15 minutes) 1
• Maximum cumulative loading dose typically 40 mg/kg 1

Evidence Supporting Phenobarbital

• Phenobarbital achieved seizure cessation in 80% of neonates in a moderate-quality randomized trial, compared to only 28% with levetiracetam (RR = 2.83,95% CI 1.78–4.50). 1
• This represents the highest quality evidence available (moderate certainty) and directly demonstrates superior efficacy over levetiracetam for first-line use. 1
• Phenobarbital showed no difference in efficacy compared to phenytoin as first-line treatment, but phenytoin is not recommended first-line due to cardiac risks. 1

Safety Considerations

• Hypotension occurs in approximately 17% of neonates treated with phenobarbital (compared to 5% with levetiracetam). 1
• Phenobarbital has been associated with potential adverse neurodevelopmental effects, necessitating the shortest duration possible. 1
• Respiratory depression risk requires airway monitoring, though serious adverse events are uncommon. 1

Special Circumstances: When NOT to Use Phenobarbital First

Suspected Channelopathy (Family History Positive)

• If self-limited familial neonatal epilepsy is suspected due to positive family history (KCNQ2/KCNQ3 variants), use phenytoin or carbamazepine (sodium channel blockers) as first-line treatment instead. 1
• 91% expert consensus supports this approach when family history suggests channelopathy. 1
• Without a positive family history, do not delay treatment—use phenobarbital immediately to avoid treatment delays. 1

Cardiac Disorders

• In neonates with pre-existing cardiac disorders, consider levetiracetam as an alternative to avoid phenytoin's cardiac complications. 1

Second-Line Treatment (If Seizures Persist After Phenobarbital)

For most etiologies (HIE, stroke, hemorrhage), phenytoin or levetiracetam may be used as second-line treatment. 1

Second-Line Options

• Phenytoin: 18 mg/kg IV over 20 minutes (requires cardiac monitoring due to 3.2% hypotension risk) 1
• Levetiracetam: 40 mg/kg IV (can give additional 20 mg/kg if needed; lower hypotension risk at 0.7%) 1
• Alternative options: Midazolam or lidocaine (less favorable) 1

Special Second-Line Considerations

• If channelopathy suspected based on clinical/EEG features (even without family history), use sodium channel blocker (phenytoin or carbamazepine) as second-line. 1
• If cardiac disorders present, prefer levetiracetam as second-line. 1

Pyridoxine Trial

Consider pyridoxine trial (add-on to ASM) in two scenarios: 1

1. Neonates with clinical features or EEG characteristics suggestive of vitamin B6-dependent epilepsy
2. Neonates with seizures unresponsive to second-line ASM without identified etiology

• If pyridoxine trial unsuccessful and vitamin B6-dependent epilepsy still suspected, consider trial of pyridoxal 5'-phosphate (PLP). 1

Duration of Treatment

Following cessation of acute provoked seizures, discontinue ASM before hospital discharge, regardless of MRI or EEG findings. 1

Rationale for Early Discontinuation

• This differs from older WHO/ILAE/IBE 2011 guidelines. 1
• Neurodevelopment and epilepsy risk at 24 months were not different between children whose ASMs were discontinued versus maintained at discharge. 1
• Early discontinuation minimizes exposure to phenobarbital's potential adverse neurodevelopmental effects. 1
• Only continue ASM beyond discharge if there is evidence of neonatal-onset epilepsy (not acute provoked seizures). 1

Common Pitfalls to Avoid

• Do not use levetiracetam as first-line treatment unless channelopathy with family history or cardiac contraindication to phenobarbital—the evidence clearly shows phenobarbital is superior. 1
• Do not treat clinically suspected seizures without EEG confirmation (except focal clonic/tonic)—this leads to treating non-seizure events and missing electrographic-only seizures. 1
• Do not continue ASM beyond discharge for acute provoked seizures—this exposes neonates to unnecessary medication risks without benefit. 1
• Do not delay phenobarbital while awaiting genetic testing unless there is a clear positive family history of channelopathy. 1
• Do not use fixed doses—always calculate weight-based dosing (20 mg/kg). 1